News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AstraZeneca PLC (AZN) Release: NHANES Analyses Reinforce The Need For Education To Help Increased Risk Dyslipidemic Patients Aggressively Treat Their Cholesterol


11/20/2013 7:52:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced the results of three analyses of data from the National Health and Nutrition Examination Survey (NHANES), all of which supported that an unmet treatment need still exists for dyslipidemia patients, particularly those at high-risk. These data were presented at the 2013 American Heart Association (AHA) Scientific Sessions in Dallas, Texas.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES